Abstract 5881: PERIO-01: Initial Safety Experience and Immunologic Effects of a Class C TLR9 Agonist Using Pressure- Enabled Drug Delivery in a Phase 1 Trial of Hepatic Arterial Infusion of SD-101 +/- Checkpoint Inhibition in Metastatic Uveal Melanoma